Winter 2024

The proteins strike back – Antibodies & more

Since the first antibody drug was approved back in 1986, monoclonal antibodies have emerged as the dominant class in the global US$417bn market for biologics. At the end of 2023, sales stood at more than US$230bn. However, after decades of development, new treatments are now hitting the market. Among them: improved versions of artificial bispecific antibodies, antibody-drug conjugates and other engineered proteins used in immunoreceptor-based therapies such as CAR-T and TCR-T cell therapies.

In this issue:

Cover story – New proteins on the block
Country alliance calls for launch of a European protein strategy
Climate paralysis at COP29 in Baku
Commission seeks industry input over Novo/Catalent deal
Financing – the Italian way for start ups
Interview: Thomas Lingelbach (Valneva SE) about the Valneva way
30 years of BIO-Europe – Spotlight Scandinavia
IP – Unified Patent Court. quo vadis?
Update of ongoing clinical trials, News from the Stock markets,
Regional news, news from BIOTECH Austria, Society for Laboratory Automation and Screening (SLAS) and the Young European Biotech Network
SPECIAL: Protein engineering